Medexus Pharmaceuticals Inc. (MEDXF)

Market Cap	44.76M
Revenue (ttm)	112.94M
Net Income (ttm)	-217.40K
Shares Out	24.46M
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	14.35
Dividend	n/a
Ex-Dividend Date	n/a

Volume	27,803
Open	1.650
Previous Close	1.620
Day's Range	1.650 - 1.830
52-Week Range	1.060 - 2.562
Beta	1.87
Analysts	n/a
Price Target	3.00 (+63.93%)
Earnings Date	Aug 6, 2024

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• CEO: Kenneth d'Entremont
• Employees: 82
• Stock Exchange: OTCMKTS
• Ticker Symbol: MEDXF